Sugi Predict

Sugi Predict / Compounds / SCHEMBL25337204

SCHEMBL25337204

SCHEMBL25337204

Cn1c(=O)[nH]c2cccc(C3CC(C(=O)N4CCN(C(=O)OC(C)(C)C)CC4)C3)c21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ SSTR1 P30872 2/20 0.39
▸ SSTR2 P30874 2/20 0.39
▸ SSTR4 P31391 2/20 0.39
▸ SSTR3 P32745 2/20 0.39
▸ SSTR5 P35346 2/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ CCR5 P51681 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ THRB P10828 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ FNTA P49354 1/20 0.37
▸ FNTB P49356 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25338184 1.00 KDM4E (0.40) KDM4EPARP1HPGDSSTR1SSTR2
SCHEMBL25340117 1.00 KDM4E (0.40) KDM4EPARP1HPGDSSTR1SSTR2
SCHEMBL8802407 0.87 THRB (0.48) KDM4EPARP1CCR5THRBMAPT
SCHEMBL25973643 0.86 CNR1 (0.43) KDM4EPARP1CCR5PDE10A
SCHEMBL25339692 0.84 KDM4E (0.50) KDM4EPARP1CCR5THRBMAPT
SCHEMBL25973876 0.81 CCR5 (0.40) PARP1CCR5
SCHEMBL25338364 0.81 CCR5 (0.40) PARP1CCR5
SCHEMBL26766523 0.81 CCR5 (0.41) PARP1CCR5
SCHEMBL25340159 0.81 CCR5 (0.41) PARP1CCR5
SCHEMBL25337092 0.79 SSTR1 (0.37) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 — — EP disclosed
CN-118973581-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2024-11-15 — — CN disclosed
US-12091411-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885PARP1 85/4885HPGD 3843/4885
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885PARP1 85/4885HPGD 3843/4885
US-12091411-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885PARP1 85/4885HPGD 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.